Skip to Main Content

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Conditions

Diseases of the Nervous System

Phase IV

What is the purpose of this trial?

Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    10/14/2015
  • End Date
    11/29/2019
Trial Image

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/22/2018
  • Study HIC
    #1401013207